Astrazeneca (AZN) Notes Payables (2009 - 2026)

Astrazeneca (AZN) has reported Notes Payables for 18 consecutive years, with -$597.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Notes Payables fell 2495.65% year-over-year to -$597.0 million; the TTM figure through Mar 2026 stood at -$597.0 million (down 2495.65% YoY), while the FY2025 annual figure was -$13.0 million, up 96.06% from the prior year.
• Notes Payables came in at -$597.0 million for Q1 2026 at Astrazeneca, up from -$644.0 million in the prior quarter.
• The five-year high for Notes Payables was $337.0 million in Q2 2022, with the low at -$805.0 million in Q1 2022.
• Average Notes Payables over 5 years is -$340.1 million, with a median of -$477.0 million recorded in 2024.
• Across the five-year window, Notes Payables soared 95.18% in 2025 and plunged 2495.65% in 2026, its largest moves.
• Year by year, Notes Payables stood at -$350.0 million in 2022, then sank by 47.14% to -$515.0 million in 2023, then soared by 35.92% to -$330.0 million in 2024, then plunged by 95.15% to -$644.0 million in 2025, then advanced by 7.3% to -$597.0 million in 2026.
• According to Business Quant data, Notes Payables over the past three periods registered -$597.0 million, -$644.0 million, and -$622.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.